Making Risk-vs.-Benefit Decisions a Little More Black-and-White?

article image

Efforts to capture subjective input, evaluate uncertainty, and feed the information into more statistically robust risk-benefit decision-making frameworks has been an important goal at FDA’s device center. Three documents recently issued by the agency nicely illustrate its current progress and thinking on the topic.

Adding more objectivity and quantification to the inherently squishy decision-making process needed to say whether the benefits of a device outweigh the risks for a particular patient population is a major goal at FDA.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: